Enzymes in essential metabolic pathways are attractive targets for the treatment of bacterial diseases, but in many cases, the presence of homologous human enzymes makes them impractical candidates for drug development. Fumarate hydratase, an essential enzyme in the tricarboxylic acid cycle, has been identified as one such potential therapeutic target in tuberculosis. We report the discovery of the first small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase. A crystal structure at 2.0Å resolution of the compound in complex with the protein establishes the existence of a novel allosteric regulatory site. This allosteric site allows for selective inhibition with respect to the homologous human enzyme. We observe a unique binding mode in which two inhibitor molecules interact within the allosteric site, driving significant conformational changes that preclude simultaneous substrate and inhibitor binding. Our results demonstrate the selective inhibition of a highly conserved metabolic enzyme that contains identical active site residues in both the host and the pathogen.
I. INTRODUCTION
Because the TCA cycle connects many pathways of cellular metabolism, preventing the function of this cycle through enzyme inhibition is an attractive strategy for targeting infectious agents 1 . In Mycobacterium tuberculosis, experimental evidence 2 has suggested that fumarate hydratase, the essential enzyme responsible for the reversible conversion of fumarate to (L)-malate, is a vulnerable target. This vulnerability is in part due to the fact that, unlike other bacteria such as Escherichia coli, M. tuberculosis expresses only one enzyme that performs this function 3 . In addition to its role in metabolism under aerobic conditions, fumarate hydratase has also garnered interest because of the discovery of a flux toward the reverse TCA cycle under hypoxic conditions in nonreplicating M. tuberculosis 2, 4, 5 . Yet, in spite of these discoveries, no small molecule inhibitor of the M. tuberculosis fumarate hydratase has been reported. The discovery of such an inhibitor would provide an important tool to begin probing the role of the TCA cycle, in both actively replicating and non-replicating bacteria.
From the standpoint of drug development, however, targeting the M. tuberculosis fumarate hydratase poses a significant challenge because the protein is highly evolutionarily conserved. In particular, the human and M. tuberculosis homologs share identical active site residues, as well as 53% overall sequence identity 6, 7 . Both homologs form a stable homotetramer containing four active sites, a) ca26@cam.ac.uk b) cbarry@niaid.nih.gov c) craigt@mail.nih.gov and every active site is composed of residues from three enzyme subunits. Each dumbbell-shaped subunit within the tetramer contains three domains: an N-terminal domain, a central domain, and a C-terminal domain [8] [9] [10] . The N-terminal and C-terminal domains are predominantly α-helical, and are linked by the central domain that consists of five tightly-packed helices. The central domains of the four subunits pack together into a 20-helix bundle to form the tetrameric structure. Each subunit organizes in a head-to-head fashion with one subunit and a head-to-tail fashion with the remaining two subunits. These structural similarities further increase the challenge of selective inhibition.
Here we report the discovery of the first selective small molecule inhibitor of the M. tuberculosis fumarate hydratase. The selectivity results from the binding of the inhibitor to a novel allosteric site composed of residues that are not conserved between the human and the M. tuberculosis homologs. Using X-ray crystallography and steady-state kinetics, we define the location of this new
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The tricarboxylic acid (TCA) cycle plays a central role in the metabolism of many pathogens, but few inhibitors of this pathway currently exist. Our study describes the first small molecule inhibitor of the fumarate hydratase enzyme in the TCA cycle of Mycobacterium tuberculosis. We also report the discovery of an allosteric regulatory site that confers selectivity of the inhibitor's activity over the homologous human enzyme. Our findings illustrate the potential to target vulnerable metabolic enzymes effectively and selectively in spite of their high degree of evolutionary conservation. binding pocket and assess the effect of the inhibitor on both enzyme structure and function. These results illustrate the potential for fumarate hydratase to be a tractable target for drug development against M. tuberculosis.
II. RESULTS

Fluorescence-based Assays to Monitor Fumarate Hydratase Enzyme Activity
In order to identify inhibitors of the M. tuberculosis fumarate hydratase, we developed a fluorescence-based assay to monitor the enzyme's activity. Inspired by others who have utilized enzyme kinetics to investigate the TCA cycle 11 , we modeled the assay after the natural progression of the cycle under aerobic conditions. In this assay design, fumarate hydratase requires coupling to a minimum of two enzymes. The first coupled enzyme, malate dehydrogenase (MDH), generates the fluorescent molecule NADH upon oxidizing (L)-malate to oxaloacetate; however, the equilibrium of this reaction favors (L)-malate. Therefore, a second coupled enzyme is required to obtain a reliable readout. We chose to include the enzyme diaphorase, which consumes the NADH from the MDH reaction and regenerates NAD + . The use of diaphorase and its substrate resazurin (7-hydroxy-3H-phenoxazin-3-one) has the additional benefit of forming the fluorescent molecule resorufin (7-hydroxy-3H-phenoxazin-3-one) as a product. Thus, we were able to monitor resorufin fluorescence at 598 nm as a means of measuring fumarate hydratase activity. The detection at a wavelength of 598 nm is preferable to commonly used shorter wavelengths such as 340 nm, where the intrinsic fluorescence of compounds in small molecule libraries results in assay interference 12 . Finally, we also incorporated the enzyme citrate synthase into the assay design, as the thermodynamically favorable cleavage of the thioester bond of acetyl-coenzyme A in this reaction significantly speeds the assay progression by shifting the equilibrium state toward the products, thereby making a high-throughput screen feasible (Fig. 1a) .
A titration of the fumarate hydratase enzyme in our final assay conditions showed proportional changes in the initial rate of the fluorescence output, indicating that we were accurately monitoring the enzyme's activity (SI Appendix, Fig. S1 ). We further tested the reliability of the assay by measuring the initial reaction rate at varying substrate concentrations. The resulting, highly reproducible saturation curve was fit using the MichaelisMenten model 13, 14 , yielding a K m of 260 +/-20 µM for fumarate (Fig. 1b) . To evaluate enzyme activity in the presence of small molecules, we elected to measure fluorescence immediately upon initiation of the reaction and again after five minutes. Five minutes was found to be a suitable timepoint, as the reaction displayed a wide signal window of 1104 +/-13 relative fluorescence units (RFU) between positive and negative (no fumarate hydratase enzyme) controls with a Z ′ factor 15 of 0.71.
Identification of Fumarate Hydratase Inhibitors using High-throughput Screening
We conducted a screen of 479,984 small molecules in a 1536-well format 16, 17 . The compound library contains a diverse set of molecules with drug-like physico-chemical properties, and also includes compounds with known biological activity 18 . Each compound was screened at four concentrations, ranging from 115 µM to 2.3 µM. We selected a group of 1,856 compounds that showed potential activity as defined by a dose-response curve class 17 of either 1 or 2, and evaluated their reproducibility by re-screening them in the assay at eleven concentrations, ranging from 115 µM to 2.0 nM. This group of compounds was also subjected to rigorous counter-screening to eliminate those molecules affecting resorufin production through mechanisms other than fumarate hydratase inhibition. Compounds affecting MDH, citrate synthase, and diaphorase activity were identified and discarded using truncated versions of the primary assay (SI Appendix, Fig. S2 ). In addition to eliminating inhibitors of the coupled enzymes, the counterassays allowed for removal of molecules that affected fluorescence due to inherent properties of the compound or due to nonspecific effects in the assay conditions. We identified two structurally similar candidate molecules that bear no overt resemblance to fumarate and (L)-malate (SI Appendix, Fig. S3 ). This observation prompted us to examine the more potent of the two compounds (N-(5-(azepan-1-ylsulfonyl)-2-methoxyphenyl)-2-(4-oxo-3,4-dihydrophthalazin-1-yl)acetamide) (7) in detail (Fig. 1c) . The compound was resynthesized to confirm its identity and purity (SI Appendix, Fig. S4 ). Subsequent revalidation of 7 revealed a highly reproducible dose-response curve with an IC 50 of 2.5 +/-1.1 µM, a maximum inhibition of 97 +/-3%, and notably, a Hill slope of 2.4 +/-0.5 (Fig. 1d) . This Hill slope suggests that a minimum of two inhibitor molecules must be functionally important for the inhibition of catalysis at a given active site 19 .
Validation of Binding using X-ray Crystallography
To validate the binding of 7 to fumarate hydratase, we performed X-ray crystallographic studies of the enzyme. We crystallized the protein in the absence of 7 in a solution containing 200 mM magnesium formate and determined the structure at 1.86Å resolution (Table S1; PDB ID: 5F92). Formate ions from the solution are bound at two of the enzyme active sites in a fashion that mimics substrate binding, with the formate carboxylate ions making identical hydrogen bonding interactions as the carboxylates of (L)-malate described in a previ- ously published structure (PDB ID: 4ADL; SI Appendix, Fig. S5 ) 9 . The binding of substrate-mimicking formate ions in two of the four available active sites is also consistent with the structure of fumarate hydratase in complex with (L)-malate. We illustrate the relative positions of the formate-bound and unoccupied active sites in Fig. S6 (SI Appendix).
To obtain a protein-inhibitor complex, we soaked the formate-bound crystals with a saturated solution of 7, resulting in a structure at 2.0Å resolution (Table S1 ; PDB ID: 5F91). Analysis of the structure reveals Fourier difference density that unambiguously identifies a binding site of two molecules of 7 approximately 20Å away from each of the two nearest active sites (Fig. 2a-b) . This novel binding site is located at the interface of the two C-terminal domains of subunits A and C. Due to the enzyme's internal symmetry, a second identical binding site should also exist between the C-terminal domains of subunits B and D; however, no inhibitor is observed at this location, most likely because the site is engaged in a crystal contact (SI Appendix, Fig. S7-S8 ).
The binding of 7 results in a dramatic conformational change, in which the C-terminal domain of subunit C rotates to interact with the inhibitor molecules (Fig. 2c) . Consistent with this observation of a significant structural rearrangement, the length of the crystallographic c-axis decreases by approximately 5Å (SI Appendix, Table S1 ). The structural change results in the loss of electron density of both the two formate ions and the active site loop 316A-323A in the nearest active site. This effect on the substrate-mimicking formate ions and the active site assembly suggests that the novel binding site is allosteric in nature.
One of the key features of the two bound inhibitor molecules is an unusual π-stacking interaction between their two core phenyl rings within the allosteric site (Fig. 2d) . This interaction between the two molecules of 7 appears to be an important contributor to binding. Furthermore, each molecule of 7 makes several key interactions with surrounding amino acids. Each inhibitor molecule interacts with the nearest Arg432 (of either subunit A or C), with the residue forming a stacking interaction with the inhibitor's quinazolinone ring and a hydrogen bond to its amide oxygen atom. In addition, the backbone oxygen atom of each Leu429 hydrogen bonds to the nitrogen atom at the 2-position of the nearest inhibitor molecule's quinazolinone ring (Fig. 2e ; SI Appendix Fig. S9 ). A stereoimage of the two molecules of 7 in their electron density, with a depiction of additional interactions with the surrounding amino acids and solvent molecules, can be found in the SI Appendix, Fig. S10 . 
Examination of the Mode of Inhibition
The loss of the two formate ions from the active site adjacent to 7 suggests that the binding of the two inhibitor molecules to the allosteric site competitively precludes substrate binding in the neighboring active sites. To investigate this further, we assessed the nature of the protein's conformational change by examining the subunit that exhibits the greatest movement upon inhibitor binding (subunit C). It has been previously reported that the C-terminal domain of each subunit of the M. tuberculosis fumarate hydratase enzyme possesses both an 'open' and a 'closed' conformational state. The 'closed' conformational state is induced upon substrate binding at the nearest active site, and involves a 34
• in-ward rotation of the C-terminal domain from the 'open' unbound form 9 . In the formate-bound structure, subunit C aligns with the 'closed' conformation of a subunit with (L)-malate bound to the nearest active site (subunit rmsd = 0.8Å, PDB ID: 4ADL), because the formate ions mimic the binding mode of the carboxylates of (L)-malate (SI Appendix, Fig. S11a ). Upon binding of 7, however, the C-terminal domain rotates outward to align with the substrate-free enzyme in the 'open' conformation (subunit rmsd = 1.3Å, PDB ID: 3NO9) (SI Appendix, Fig. S11b ). This movement suggests that inhibitor binding stabilizes the subunit's Cterminal domain in an 'open'-like form, thereby preventing substrate binding and catalysis in a competitive fashion (Fig. 3a) . Notably, the C-terminal domain of subunit A, which also contributes to the allosteric site, remains in the 'open' conformation in both the formate-bound and the 7-bound structures because its adjacent active site is always unoccupied.
The effect of the inhibitor on the residues of the allosteric site and the adjacent active site is illustrated in Fig. 3b . Upon binding of 7, Leu429C and Arg432C shift to form interactions with the inhibitor within the allosteric site (Fig. 3b , top inset). In the adjacent active site, the electron density of the two formate ions is lost. Notably, the conformational change affects active site assembly by increasing the flexibility of the loop residues 316A-323A, such that these residues can no longer be modeled in the 7-bound structure (SI Appendix, Fig. S12 ). The loss of the electron density of this loop is significant because two of the residues, Ser318A and Ser319A, form critical hydrogen bonds with formate ions in the formate-bound structure. This change in the active site is likely an effect of the concerted motion of the C-terminal domain of subunit C induced by the binding of 7. The movement of the C-terminal domain of subunit C from the 'closed' conformation to the 'open' conformation eliminates the stabilizing interaction between Asn413C and the backbone oxygen atom of the loop residue Ile320A (SI Appendix, Fig. S13 ). The loss of this interaction likely contributes to the increased flexibility of the critical loop residues 316A-323A at the active site. Additional active site residues are also affected in the inhibitor-bound structure. Lys324A and Ser139D, which both form hydrogen bonds with the formate ions in the formate-bound structure, are displaced in the 7-bound structure. As a result of the movement, the γ-oxygen of Ser139D occupies the former location of a formate ion (Fig. 3b, bottom inset) . Together, these changes in the active site upon binding of 7 suggest that simultaneous binding of inhibitor and substrate cannot occur and that 7 is a competitive inhibitor of enzyme activity.
In addition to the structural evidence, we also assessed the mechanism of inhibition of 7 in solution using steadystate kinetic experiments. We generated a matrix of reaction progress curves for fumarate hydratase in the presence of varying concentrations of substrate and 7, and then plotted the enzymatic saturation curves at each inhibitor concentration. Given that substrate cooperativity was not observed at the fumarate concentrations used in the assay, the kinetic data was analyzed with respect to an independent catalytic site. Furthermore, because the crystal structure suggests that the binding of two inhibitor molecules disrupts active site assembly, the model for determining mode of inhibition was modified to incorporate the equilibrium binding of two inhibitor molecules (Fig. 3c) . The rate equation derived from this model represents general mixed inhibition (see equation (1) in Materials and Methods). [All standard models of inhibition (competitive, non-competitive, uncompetitive, mixed) are incorporated within this model, and upon fitting of a data set, the model may reduce to a specific case depending on the resultant K i values 20 .]
We fit the rate equation for the model shown in Fig. 3c to our kinetic data (Fig. 3d) , and the resulting K i values support a competitive mode of inhibition. The values for K i1 and K i2 , which represent the affinity of the inhibitor for the enzyme without substrate bound, were found to be 6.3 +/-4.4 µM and 3.2 +/-0.3 µM, respectively. By contrast, K i3 and K i4 , which represent the affinity of the inhibitor for the enzyme-substrate complex, were found to contribute negligibly to the fit ((1/K i3 ) < 10
and (1/K i4 ) < 10 −16 ). This suggests that the binding of the inhibitor to the enzyme alone results in inhibition in a purely competitive fashion. The values of apparent V max and apparent K m for the fits shown in Fig. 3d have been calculated for each inhibitor concentration and are presented in Table S2 (SI Appendix). Consistent with competitive inhibition, apparent V max does not change as inhibitor concentration increases, while the apparent K m is observed to increase.
Allosteric Site Binding Confers Selectivity
Following the identification of the allosteric site, we aligned the amino acid sequences of the M. tuberculosis and the human fumarate hydratase enzymes (SI Appendix, Fig. S14a ). The alignment reveals that, despite a 53% sequence identity and identical active site residues, the allosteric site residues making direct interactions with the inhibitor molecules are not conserved in the human homolog (SI Appendix, Fig. S14b) . The difference in these amino acid residues suggests the potential for selectivity of 7 over the human enzyme.
In order to investigate this hypothesis, we modified the enzymatic assay shown in Fig. 1a to report on human fumarate hydratase activity (SI Appendix, Fig. S14c-d) . We then treated the human enzyme with 7 at concentrations up to 122 µM. We observed no inhibition of the human enzyme, indicating that 7 is highly selective (SI Appendix, Fig. S14e ). The striking difference in the effect of 7 on the activity of the two enzymes is illustrated in Fig. 1d . In the absence of substrate or substrate mimic, the C-terminal domain of subunit C adopts the 'open' conformation (left). When (L)-malate or formate is bound to the active site, the C-terminal domain of subunit C adopts the 'closed' conformation (center). In the presence of the allosteric inhibitor, subunit C shifts to the 'open' conformation (right). The electron density for the formate ions is lost, suggesting that substrate and inhibitor cannot be simultaneously bound. (b) A depiction of the fumarate hydratase active site and allosteric site when formate is bound (gray structure, formate in yellow) or 7 is bound (colored structure). Upon binding of 7, the Cterminal domain of subunit C (purple) rotates into the 'open' conformation. At the allosteric site, Leu429C and Arg432C shift toward the inhibitor (top inset). At the active site, the binding of 7 results in the loss of electron density of the loop residues 316A-323A, as well as the movement of active site residues Lys324A and Ser139D (bottom inset). These active site residues form critical hydrogen bonds (dashed lines) to the substrate-mimicking formate ions in the formate-bound structure. (c) The equilibrium binding model that accounts for two molecules of inhibitor (I) binding to the enzyme (E) or enzyme-substrate complex (ES) in the presence of substrate (S) and product (P). 
Effect of the Inhibitor on M. tuberculosis H37Rv
In order to evaluate the potential of 7 in a biological context, we examined the effect of our hit compound on the survival and growth of M. tuberculosis H37Rv. When evaluating survival via detection of colony-forming units, we did not observe any bactericidal effect when cells were treated with 7 under either aerobic or anaerobic conditions (SI Appendix, Fig. S15 and SI Methods). However, treatment of H37Rv with 7 under aerobic conditions resulted in a dose-dependent effect on bacterial growth rate (Fig. 4) . Cells constitutively expressing green fluorescent protein (GFP) 21 were used to monitor the growth rate of the bacteria. Twelve days after treatment with 7 at a concentration of 250 µM, bacterial cells exhibited 35 +/-6% growth relative to a vehicle-treated control culture. The growth rate could not be monitored in a similar fashion under anaerobic conditions as these cells are non-replicating.
While we were able to measure a dose-dependent change in bacterial growth rate under aerobic conditions in the presence of 7, the magnitude of this effect is small. The observed effect could be limited by the hit compound's potency and cell permeability, or the effect could be the result of an off-target mechanism within the cell. To investigate these possibilities, a medicinal chemistry campaign to optimize the aforementioned properties of the hit compound will be required.
III. DISCUSSION
Although the properties of fumarate hydratase enzymes have been studied extensively since the 1950s [22] [23] [24] [25] , reports of targeted small molecule modulators of their activity have been scarce. Pyromellitic acid (benzene-1,2,4,5-tetracarboxylic acid) has been previously reported as a weak inhibitor of some fumarate hydratase homologs 26 , but it shows no inhibitory activity with respect to the M. tuberculosis enzyme. We have identified the first effective and selective small molecule inhibitor of the M. tuberculosis fumarate hydratase. The structural features of our hit compound immediately suggest a potential allosteric effect. The compound lacks acidic functional groups to mimic substrate binding at the active site, and its molecular weight is more than triple that of the enzyme's natural substrates. A crystal structure of our hit bound to fumarate hydratase has identified the location of an allosteric site as well as provided a rationale for the observed selectivity over the homologous human enzyme.
In addition to the location of an allosteric site, the crystal structure has also revealed an unusual compound binding mode, with two molecules bound at the interface of two protein subunits. While this structural information provides a guide for the rational design of additional inhibitors, modifications to the compound structure that preserve potency may be challenging to identify. Compound analogs must not only preserve interactions with the enzyme but also maintain the stacking interactions between the two inhibitor molecules. One potential design strategy would be to explore an array of linkers to join the two inhibitor molecules. Importantly, design strategies should take advantage of the knowledge that the allosteric inhibitor appears to prevent catalysis by locking the enzyme subunits in an 'open' conformation, in which the substrate cannot bind. With this in mind, any small molecule or peptidomimetic that stabilizes the open conformation of the enzyme could potentially be an effective inhibitor.
The discovery of an allosteric regulatory site raises the possibility that a natural biomolecule binds to fumarate hydratase at this location in vivo. Although we were unable to identify such a biomolecule, it is certainly possible that the allosteric site serves a yet unknown biological function. This function could be limited to simple regulation of enzymatic activity, or it could involve a second, unrelated process. Dual functions of several metabolic enzymes have recently been reported [27] [28] [29] [30] , and, in particular, the human fumarate hydratase has been implicated in the DNA damage response [31] [32] [33] . The existence of these dual functions of metabolic enzymes suggests that potential biological functions of this novel allosteric site deserve further exploration.
While many inhibitors exist for M. tuberculosis enzymes in metabolic pathways ranging from glycolysis 34 to sulfur metabolism 35 , there are, to our knowledge, no reported inhibitors that target the TCA cycle in this or-ganism. This dearth of inhibitors is likely due to both the redundancy as well as the evolutionary conservation of many enzymes in the pathway. Our work, however, exposes a vulnerability in this pathway in the form of an allosteric site that could be exploited to target these bacteria. When treating H37Rv cells with the allosteric inhibitor under aerobic conditions, we observe a decrease in bacterial growth rate. Although we cannot rule out the possibility that this result is due to an off-target mechanism, the presence of a dose-dependent effect on growth in a biological context supports further investigation to optimize the potency, solubility, and cell permeability of this molecule for greater biological activity. This optimization would facilitate studies to verify the mechanism of the compound's biological effect and to assess the role of fumarate hydratase in various environments. In identifying the first small molecule inhibitor of the M. tuberculosis fumarate hydratase and characterizing its binding to a novel allosteric site, we illustrate the feasibility of selectively inhibiting this highly conserved metabolic enzyme, while providing a starting point for the development of these more potent probes.
IV. MATERIALS AND METHODS
High-throughput Screen and Counterscreens
The M. tuberculosis fumarate hydratase was expressed and purified as described in the SI Appendix. The high-throughput screens were run in 1,536-well plates with a final well volume of 4 µL. All measurements were performed in 50 mM Tris pH 8, 5 mM MgCl 2 , 0.01% Brij 35.
Final concentrations of reagents were as follows: 10 nM M. tuberculosis fumarate hydratase, 10 units/mL MDH, 1 unit/mL citrate synthase, 150 µM NAD + , 200 µM acetyl-CoA, 0.05 mg/mL diaphorase, 0.05 mM resazurin, and 400 µM fumaric acid. All reagents with the exception of the purified fumarate hydratase were purchased from Sigma-Aldrich. Detailed protocols for the high-throughput screen and counterscreens can be found in the SI Appendix.
Synthesis and Compound Characterization of 7
The synthetic scheme for the preparation of 7 (Fig. S4 ) and the detailed compound characterization (SI Methods) can be found in the SI Appendix.
Crystallization, Data Processing, and Structure Determination
For the formate-bound structure, crystals were grown by sitting drop vapor diffusion at 20
• C in 17.0% [w/v] PEG3350, 5% [v/v] DMSO, and 200 mM magnesium formate, by combining 2 µL of a 14 mg/mL protein solution (10 mM Tris pH 8.0, 150 mM NaCl, and 0.5 mM TCEP) with 1 µL of reservoir.
The Detailed methods on crystallization trials, data processing, and structure determination can be found in the SI Appendix. Coordinates and structure factors for the formate-bound structure and the complex with 7 have been deposited in the Protein Data Bank under accession numbers 5F92 and 5F91, respectively.
Mode of Inhibition Steady-state Kinetic Assay
The mode of inhibition assay was run in 1,536-well plates under the same conditions as the primary highthroughput screen described above, with the following modifications: (1) a new batch of enzyme was purified for this study, resulting in the fumarate hydratase concentration being lowered to 1.25 nM and (2) to prevent pH changes at high substrate concentrations, sodium fumarate dibasic was used in place of fumaric acid to initiate the reaction. The inhibitor was tested in a sevenpoint dilution ranging from 28.6 µM to 447 nM. Nine concentrations of sodium fumarate dibasic, ranging from 0 mM to 6.4 mM were tested. Each plate was read in kinetic mode on a ViewLux High-throughput CCD imager (Perkin-Elmer) equipped with standard UV fluorescence optics (525 nm excitation, 598 nm emission) for 10 minutes. The change in fluorescence intensity over the 10-minute reaction period was normalized against no-substrate controls and the resulting initial reaction rates were plotted. The enzymatic saturation curves were fit using the following rate equation derived using the steady-state approximation from the model of general mixed inhibition pictured in Fig. 3c :
.
Human Fumarate Hydratase Selectivity
The selectivity assay was conducted in 384-well black Greiner plates with a final well volume of 40 µL. All measurements were performed in 50 mM Tris pH 8, 5 mM MgCl 2 , 0.01% Brij 35.
Final concentrations of reagents were as follows: 10 nM human fumarate hydratase (Sigma-Aldrich), 10 units/mL MDH, 1 unit/mL citrate synthase, 150 µM NAD + , 200 µM acetyl-CoA, 0.05 mg/mL diaphorase, 0.05 mM resazurin, and 400 µM fumaric acid. A detailed assay protocol can be found in the SI Appendix.
Growth Rate of H37Rv under Aerobic Conditions
An M. tuberculosis strain H37Rv containing a plasmid with the gfp gene encoding GFP under control of the constitutive msp12 promoter of M. marinum was used to monitor growth. As the plasmid contains a selectable kanamycin marker, cultures were maintained in 25 µg/mL kanamycin in 7H9 medium (Difco) supplemented with 4 g/L glucose and 0.3 g/L casitone (Difco). Experiments were conducted in black, clear-bottom 96-well plates (Greiner). Early log phase cultures were diluted 125-fold, and 50 µL was plated into each well. 50 µL of a 2x compound solution was added to the cells. Compound 7 was dosed at concentrations ranging from 16 µM to 250 µM. Each plate contained an isoniazid control, dosed at concentrations ranging from 0.07 µM to 19 µM. Plates were incubated at 37
• C and read every 2 days for 12 days on an OPTIMA microplate reader (BMG Labtech) using the bottom-read setting with excitation at 485 nm and emission at 520 nm. 
37
• C on lysogeny broth (LB) agar supplemented with 100 µg/mL ampicillin.
A single freshly transformed cell colony was grown in a starter culture (10 mL of LB media containing 100 µg/mL ampicillin) at 37
• C with shaking for 5 h. The starter culture was used to inoculate 1 L of LB media (100 µg/mL ampicillin), and the culture was grown at 37
• C with shaking to an OD 600 of ∼0.6 before induction with 0.5 mM isopropyl-β-Dthiogalactopyranoside (IPTG). The temperature of the system was decreased to 15
• C, and the culture was grown for an additional 16 h. The cells were harvested by centrifugation (4,000 rpm, 20 min, 4
• C) using a Beckman Coulter Avanti J-20 XP centrifuge.
Cell pellets were resuspended in 10 mM imidazole in lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl). Cells were lysed using a French press and centrifuged (16,000 rpm, 1 h, 4
• C).
Chromatography was conducted using an Akta FPLC (GE Healthcare). The lysate was loaded onto a HisTrap TM FF column (GE Healthcare) equilibrated with 10 mM imidazole in lysis buffer. The column was washed using 12 column volumes of 10 mM imidazole in lysis buffer, and the protein was eluted using a 20 column volume gradient of 10 mM to 1 M imidazole in lysis buffer. Fractions containing the fumarate hydratase protein were pooled and further purified on a Superdex 200 16/600 column (GE Healthcare), equilibrated with 10 mM Tris pH 8.0, 150 mM NaCl, and 0.5 mM TCEP. A centrifugal concentrator was used to yield purified protein, and the concentration was determined by amino acid analysis.
Aliquots were flash-frozen in liquid nitrogen and stored at -80 • C until further use.
High-throughput Screen and Counterscreens
For the primary high-throughput screen, 3 µL of a (4/3)x solution containing all reagents except fumaric acid were dispensed into a 1,536-well Greiner black plate via a BioRAPTR dispenser (Beckman Coulter). 23 nL of compounds were single-pin transferred via a pin tool (Kalypsys) equipped with 1536 slotted pins (V&P Scientific). The plates were incubated for 10 min at room temperature. 1 µL of a 4x solution of fumaric acid was dispensed into the plate via the BioRAPTR dispenser. The plate was centrifuged for 15 s at 1,000 rpm and read immediately on a ViewLux High-throughput CCD imager (Perkin-Elmer) using a filter set with excitation at 525 nm and emission at 598 nm. The plate was read again after 5 min. The change in fluorescence intensity between the two reads was normalized against no-inhibitor and no-enzyme controls and the resulting percent inhibition data were plotted.
Compounds were plated as four-point titrations as previously described [1, 2] .
The citrate synthase counterscreen modified the primary high-throughput screening protocol in the following ways: (1) the citrate synthase and acetyl-CoA components were removed from the reagent mixture and (2) X-ray data were collected at a wavelength of 0.969Å at beamline I24 and at 0.979Å at beamline I04 of the Diamond Light Source synchrotron (Oxfordshire, United Kingdom).
Both structures were solved by molecular replacement using PHASER [3] . The unbound M. tuberculosis fumarate hydratase (PDB ID: 3NO9) was used as a search model for the formate-bound structure, and the formate-bound structure was used as a search model for the 7-bound structure. For the formate-bound structure, automated model rebuilding was performed using Buccaneer [4] followed by manual rebuilding and refinement in Coot [5] .
The 7-bound structure was manually rebuilt in Coot, based on the molecular replacement solution from PHASER. Structures were refined using Refmac5 [6] in the CCP4 program suite [7] and the Phenix suite [8] , with 5% of the reflections excluded from refinement for R free calculations.
Some of the residues from the N-and C-termini of each subunit and from the loop of residues 315 -323 were omitted from the models due to missing electron density. The metronidazole control was dosed at 100 µM, and the isoniazid control was dosed at 10 µg/mL. The plate was incubated in the anaerobic chamber at 37
• C for 7 days. Cells were diluted by 10 3 and 10 4 , and 100 µL was plated onto 10 cm 7H11-agar containing plates. The plates were incubated at 37
• C for 5 weeks and then viable colonies were counted. 
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